Abstract:Objective Following hypoxic–ischemic (HI) brain injury, neuronal cytoplasmic chloride concentration ([Cl−]i) increases, potentially contributing to depolarizing γ‐aminobutyric acid (GABA) responses, onset of seizures, and the failure of antiepileptic drugs that target inhibitory chloride‐permeable GABAA receptors. Post‐HI seizures characteristically begin hours after injury, by which time substantial accumulation of [Cl−]i may have already occurred. In immature neurons, a major pathway for Cl− influx is the reversible Na+‐K+‐2Cl− cotransporter NKCC1. Methods Spontaneous neuronal network, neuronal [Cl−]i, and GABA activity were determined in hippocampal preparations from neonatal Clomeleon and SuperClomeleon/DLX‐cre mice to test whether blocking NKCC1 earlier after oxygen–glucose deprivation (OGD) injury would more effectively ameliorate the increase in [Cl−]i, ictallike epileptiform discharges (ILDs), and the failure of the GABAergic anticonvulsant phenobarbital. Results In vitro, murine intact hippocampi were free of ILDs for 12 h after preparation. Transient OGD resulted in a gradual increase in [Cl−]i, depolarizing action of GABA, and facilitation of neuronal network activity. Spontaneous ILDs began 3–5 h after injury. Blocking NKCC1 with 2–10 μmol·L−1 bumetanide reduced [Cl−]i equally well when applied up to 10 h after injury. Whereas phenobarbital or bumetanide applied separately were less effective when applied later after injury, ILDs were successfully suppressed by the combination of phenobarbital and bumetanide regardless of the number of prior ILDs or delay in application. Significance The present age‐specific group studies demonstrate that after OGD, NKCC1 transport activity significantly contributes to progressive [Cl−]i accumulation, depolarizing action of GABA, and delayed onset of ILDs. In this neonatal model of neuronal injury and ILDs, earlier treatment with bumetanide alone more efficiently recovered control baseline [Cl−]i and depressed epileptiform discharges. However, there was no time dependency to the anti‐ictal efficacy of the combination of phenobarbital and bumetanide. These in vitro results suggest that after perinatal injury, early pre‐emptive treatment with phenobarbital plus bumetanide would be as efficacious as late treatment after seizures are manifest.

Bumetanide enhances phenobarbital efficacy in a neonatal seizure model

Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures

A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia

The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice

The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures

Bumetanide augments the neuroprotective efficacy of phenobarbital plus hypothermia in a neonatal hypoxia-ischemia model

Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective

Acute and chronic efficacy of bumetanide in an in vitro model of posttraumatic epileptogenesis

Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models

Bumetanide potentiates the anti-seizure and disease-modifying effects of midazolam in a noninvasive rat model of term birth asphyxia

Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies

A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures

Timing of interventions to control neuronal chloride elevation in a model of neonatal seizures after hippocampal injury

Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy

Bumetanide reduce the seizure susceptibility induced by pentylenetetrazol via inhibition of aberrant hippocampal neurogenesis in neonatal rats after hypoxia-ischemia.

High Doses of ANA12 Improve Phenobarbital Efficacy in a Model of Neonatal Post-Ischemic Seizures

Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice

Enhancing GABAergic Tonic Inhibition Reduces Seizure-Like Activity in the Neonatal Mouse Hippocampus and Neocortex

Lacosamide decreases neonatal seizures without increasing apoptosis

A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy

Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic actions